DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.90 Insider Own27.70% Shs Outstand58.62M Perf Week7.49%
Market Cap900.06M Forward P/E- EPS next Y-2.19 Insider Trans8.51% Shs Float47.75M Perf Month24.88%
Income-285.60M PEG- EPS next Q-0.66 Inst Own68.00% Short Float14.06% Perf Quarter52.05%
Sales100.20M P/S8.98 EPS this Y-8.10% Inst Trans-4.63% Short Ratio5.40 Perf Half Y28.00%
Book/sh4.63 P/B2.88 EPS next Y17.70% ROA-62.10% Target Price10.78 Perf Year-63.97%
Cash/sh3.80 P/C3.51 EPS next 5Y21.00% ROE-81.40% 52W Range6.51 - 38.91 Perf YTD36.64%
Dividend- P/FCF- EPS past 5Y-43.60% ROI-98.50% 52W High-65.69% Beta1.14
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin96.90% 52W Low105.07% ATR0.84
Employees280 Current Ratio3.70 Sales Q/Q15.90% Oper. Margin- RSI (14)61.12 Volatility6.63% 7.19%
OptionableYes Debt/Eq0.00 EPS Q/Q24.60% Profit Margin- Rel Volume0.77 Prev Close13.73
ShortableYes LT Debt/Eq0.00 EarningsMay 04 BMO Payout- Avg Volume1.24M Price13.35
Recom2.70 SMA2012.79% SMA5020.79% SMA200-6.84% Volume951,706 Change-2.77%
Feb-28-22Downgrade Barclays Equal Weight → Underweight $11 → $6
Nov-08-21Downgrade Stifel Buy → Hold $60 → $10
Nov-08-21Downgrade Canaccord Genuity Buy → Hold $72 → $12
Nov-08-21Downgrade Barclays Overweight → Equal Weight $50 → $11
Nov-05-21Downgrade Truist Buy → Hold $65 → $10
Sep-30-21Resumed Stifel Buy $60
Mar-31-21Initiated Credit Suisse Outperform $78
Feb-10-21Upgrade SVB Leerink Mkt Perform → Outperform $70
Dec-03-20Initiated Stifel Buy $75
Sep-14-20Resumed JP Morgan Neutral $52
May-07-20Downgrade Nomura Buy → Neutral $84 → $60
Mar-04-20Initiated Barclays Overweight $70
Dec-20-19Reiterated Jefferies Buy $53 → $77
Oct-29-19Upgrade SVB Leerink Underperform → Mkt Perform $29 → $34
Oct-22-19Initiated JMP Securities Mkt Outperform
Oct-03-19Initiated H.C. Wainwright Buy $60
Sep-30-19Initiated Jefferies Buy $47
Jul-18-19Initiated Deutsche Bank Buy $42
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Jun-16-22 07:00AM  
Jun-15-22 11:10AM  
Jun-03-22 11:31AM  
Jun-02-22 07:00AM  
May-11-22 02:43PM  
May-06-22 11:02AM  
11:01AM  
10:37AM  
May-05-22 11:30AM  
May-04-22 02:21PM  
08:25AM  
07:00AM  
May-02-22 09:55AM  
08:00AM  
Apr-29-22 04:05PM  
03:12PM  
02:25PM  
Apr-28-22 02:35PM  
11:12AM  
Apr-27-22 08:45AM  
07:42AM  
12:02AM  
Apr-26-22 04:10PM  
03:01PM  
Apr-22-22 12:08PM  
07:39AM  
Apr-15-22 09:55AM  
Apr-12-22 03:50PM  
Mar-10-22 11:30AM  
Mar-09-22 07:00AM  
Mar-03-22 04:19AM  
Feb-09-22 12:01PM  
Feb-08-22 05:15PM  
04:05PM  
01:38PM  
Feb-07-22 09:53AM  
Feb-02-22 07:00AM  
Feb-01-22 03:01PM  
07:00AM  
Jan-24-22 05:00PM  
Jan-10-22 07:00AM  
Jan-03-22 07:00AM  
Dec-24-21 12:38AM  
Dec-21-21 08:44AM  
Dec-10-21 01:01PM  
Dec-09-21 12:09PM  
Dec-08-21 07:38PM  
07:38PM  
Dec-03-21 07:24AM  
Dec-02-21 11:31AM  
10:28AM  
Dec-01-21 11:53AM  
11:45AM  
Nov-30-21 06:11PM  
04:52PM  
01:16PM  
08:30AM  
Nov-29-21 11:40AM  
Nov-24-21 10:07AM  
Nov-23-21 11:52AM  
Nov-22-21 07:00AM  
Nov-16-21 01:20PM  
Nov-08-21 07:24AM  
Nov-05-21 12:35PM  
10:55AM  
08:40AM  
07:00AM  
Nov-03-21 11:05AM  
12:30AM  
Nov-02-21 05:15PM  
04:01PM  
Oct-26-21 09:34AM  
07:00AM  
Oct-22-21 06:13AM  
Oct-15-21 10:08AM  
Oct-12-21 07:00AM  
Oct-07-21 09:00AM  
Oct-06-21 08:34AM  
Sep-17-21 10:57AM  
08:17AM  
07:00AM  
Sep-10-21 07:00AM  
Sep-02-21 11:31AM  
07:00AM  
Aug-18-21 08:19AM  
Aug-04-21 09:07AM  
08:01AM  
Aug-03-21 05:15PM  
04:01PM  
Jul-29-21 05:31PM  
Jul-27-21 03:02PM  
07:00AM  
06:13AM  
Jul-20-21 09:47AM  
Jul-01-21 10:32AM  
Jun-30-21 04:01PM  
Jun-19-21 04:50AM  
Jun-08-21 03:16PM  
Jun-04-21 09:00AM  
Jun-03-21 11:31AM  
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Matthew LEVP & Chief Medical OfficerJun 16Sale10.751,76819,00676,884Jun 21 04:37 PM
Martin Daniel C.Chief Commercial OfficerJun 16Sale10.751,31114,09349,521Jun 21 04:35 PM
Pitman JamaSee RemarksJun 16Sale10.751,29813,95436,661Jun 21 04:36 PM
Flynn Daniel LeeChief Scientific OfficerJun 16Sale10.751,76819,00646,098Jun 21 04:34 PM
Kelly Thomas PatrickChief Financial OfficerJun 16Sale10.751,76819,00646,080Jun 21 04:35 PM
Brightstar Associates LLC10% OwnerApr 29Buy10.001,478,97814,789,78018,051,348Apr 29 04:31 PM
Kelly Thomas PatrickChief Financial OfficerFeb 16Sale9.051,36812,38047,848Feb 18 05:01 PM
Sherman Matthew LEVP & Chief Medical OfficerFeb 16Sale9.059848,90576,790Feb 18 05:01 PM
Martin Daniel C.Chief Commercial OfficerFeb 16Sale9.051,14610,37148,668Feb 18 05:01 PM
Flynn Daniel LeeChief Scientific OfficerFeb 16Sale9.051,36612,36247,866Feb 18 05:01 PM
Pitman JamaSee RemarksFeb 16Sale9.051,14610,37137,959Feb 18 05:00 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 04Sale33.172,65988,19946,029Oct 06 04:00 PM